Search

Your search keyword '"Visser, Hein"' showing total 25 results
Start Over Author "Visser, Hein"
25 results on '"Visser, Hein"'

1. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Author

Fürstenau, Moritz, Kater, Arnon P, Robrecht, Sandra, von Tresckow, Julia, Zhang, Can, Gregor, Michael, Thornton, Patrick, Staber, Philipp B, Tadmor, Tamar, Lindström, Vesa, Juliusson, Gunnar, Janssens, Ann, Levin, Mark-David, da Cunha-Bang, Caspar, Schneider, Christof, Goldschmidt, Neta, Vandenberghe, Elisabeth, Rossi, Davide, Benz, Rudolf, Nösslinger, Thomas, Heintel, Daniel, Poulsen, Christian B, Christiansen, Ilse, Frederiksen, Henrik, Enggaard, Lisbeth, Posthuma, Eduardus F M, Issa, Djamila E, Visser, Hein P J, Bellido, Mar, Kutsch, Nadine, Dürig, Jan, Stehle, Alexander, Vöhringer, Matthias, Böttcher, Sebastian, Schulte, Clemens, Simon, Florian, Fink, Anna-Maria, Fischer, Kirsten, Holmes, Emily E, Kreuzer, Karl-Anton, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Hallek, Michael, Niemann, Carsten U, and Eichhorst, Barbara

Published
2024
Full Text
View/download PDF

2. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Author

Beckers, M. M. J., Bekker, A., Bellido, M., de Boer, F., Broers, R., Chamuleau, M., Croockewit, A. J., Dompeling, E. C., Eefting, M., van Gelder, M., Hoogendoorn, M., Houtenbos, I., Doorduijn, J. K., Droogendijk, J., van der Griend, R., de Heer, K., Henkens, C. M. A., Idink, C. A. M., Issa, D. E., van Kampen, R., Kater, A. P., Kersting, S., van der Klift, M., Laterveer, L., Levenga, H., Levin, M-D., Mous, R., Nijland, M., Nijziel, M., van Norden, Y., Posthuma, E. F. M., te Raa, G. D., Raymakers, R. A. P., Regelink, J. C., Sandberg, Y., Schaafsma, M. R., Silbermann, M. H., van der Spek, A. C., van der Straaten, H. M., Tanis, B., Terpstra, W. E., Tick, L. W., Tonino, S. H., Veelken, J. H., Velders, G. A., Vlasveld, L., Visser, H. P. J., Vos, J. M. I., Wittebol, S., van Zaanen, H. C. T., van der Straten, Lina, Stege, Claudia A. M., Kersting, Sabina, Nasserinejad, Kazem, Dubois, Julie, Dobber, Johan A., Mellink, Clemens H. M., van der Kevie-Kersemaekers, Anne-Marie F., Evers, Ludo M., de Boer, Fransien, Koene, Harry R., Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A., van der Spek, Ellen, van der Straaten, Hanneke M., Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F. M., Visser, Hein P. J., Houtenbos, Ilse, Idink, Cecile A. M., Issa, Djamila E., Dompeling, Ellen C., van Zaanen, Henk C. T., Veelken, J. Hendrik, Levenga, Henriette, Tick, Lidwine W., Terpstra, Wim E., Tonino, Sanne H., Westerweel, Peter E., Langerak, Anton W., Kater, Arnon P., and Levin, Mark-David

Published
2023
Full Text
View/download PDF

3. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

Author

Kersting, Sabina, Dubois, Julie, Nasserinejad, Kazem, Dobber, Johan A, Mellink, Clemens, van der Kevie-Kersemaekers, Anne-Marie F, Evers, Ludo M, de Boer, Fransien, Koene, Harry R, Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A, van der Spek, Ellen, van der Straaten, Hanneke M, Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F M, Visser, Hein P J, Houtenbos, Ilse, Idink, Cecile A M, Issa, Djamila E, Dompeling, Ellen C, van Zaanen, Henk C T, Veelken, Hendrik, Levenga, Henriette, Tick, Lidwine W, Terpstra, Wim E, Tonino, Sanne H, Boyer, Michelle, Mobasher, Mehrdad, Levin, Mark-David, and Kater, Arnon P

Published
2022
Full Text
View/download PDF

5. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Author

van der Straten, Lina, primary, Stege, Claudia A. M., additional, Kersting, Sabina, additional, Nasserinejad, Kazem, additional, Dubois, Julie, additional, Dobber, Johan A., additional, Mellink, Clemens H. M., additional, van der Kevie-Kersemaekers, Anne-Marie F., additional, Evers, Ludo M., additional, de Boer, Fransien, additional, Koene, Harry R., additional, Schreurs, John, additional, van der Klift, Marjolein, additional, Velders, Gerjo A., additional, van der Spek, Ellen, additional, van der Straaten, Hanneke M., additional, Hoogendoorn, Mels, additional, van Gelder, Michel, additional, Posthuma, Eduardus F. M., additional, Visser, Hein P. J., additional, Houtenbos, Ilse, additional, Idink, Cecile A. M., additional, Issa, Djamila E., additional, Dompeling, Ellen C., additional, van Zaanen, Henk C. T., additional, Veelken, J. Hendrik, additional, Levenga, Henriette, additional, Tick, Lidwine W., additional, Terpstra, Wim E., additional, Tonino, Sanne H., additional, Westerweel, Peter E., additional, Langerak, Anton W., additional, Kater, Arnon P., additional, and Levin, Mark-David, additional

Published
2023
Full Text
View/download PDF

7. P1523: IMMUNOGENICITY OF THE 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE FOLLOWED BY THE 23-VALENT POLYSACCHARIDE VACCINE IN CHRONIC LYMPHOCYTIC LEUKEMIA

Author

Haggenburg, Sabine, primary, Garrido, Hannah Garcia, additional, Kant, Iris, additional, van der Straaten, Hanneke, additional, Boer, Fransien De, additional, Kersting, Sabina, additional, Issa, Djamila, additional, Raa, Doreen Te, additional, Visser, Hein, additional, Kater, Arnon, additional, Goorhuis, Abraham, additional, and Heer, Koen De, additional

Published
2023
Full Text
View/download PDF

8. Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia

Author

Haggenburg, Sabine, primary, Garcia Garrido, Hannah M., additional, Kant, Iris M. J., additional, Van der Straaten, Hanneke M., additional, De Boer, Fransien, additional, Kersting, Sabina, additional, Issa, Djamila, additional, Te Raa, Doreen, additional, Visser, Hein P. J., additional, Kater, Arnon P., additional, Goorhuis, Abraham, additional, and De Heer, Koen, additional

Published
2023
Full Text
View/download PDF

9. Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Author

Kersten, Marie José, primary, Dreyling, Martin, additional, Linton, Kim M., additional, Chitu, Dana, additional, Tonino, Sanne, additional, Kap, Marcel, additional, Liu, Roberto D, additional, Chamuleau, Martine E.D., additional, Visser, Hein P.J., additional, De Jongh, Eva, additional, Marijt, Erik WAF, additional, Leijs, Maria B.L., additional, Bilgin, Yavuz M., additional, Dürig, Jan, additional, McKay, Pamela, additional, Snijders, Tjeerd J.F., additional, Pettitt, Andrew, additional, Minnema, Monique C., additional, Prange-Krex, Gabriele, additional, Cuijpers, Maria, additional, Böhmer, Lara H., additional, Tick, Lidwine W., additional, Florschütz, Axel, additional, Silbermann, Matthijs, additional, Fijnheer, Rob, additional, Beeker, Aart, additional, Tolboom, Nelleke, additional, Mitea, Cristina, additional, Arens, Anne IJ, additional, Zwezerijnen, Gerben JC, additional, Klapper, Wolfram, additional, Coupland, Sarah E., additional, de Jong, Daphne, additional, Doorduijn, Jeanette K., additional, and Zijlstra, Josée M., additional

Published
2022
Full Text
View/download PDF

10. Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients with Chronic Lymphocytic Leukaemia

Author

Haggenburg, Sabine, primary, Garcia Garrido, Hannah, additional, Kant, Iris, additional, De Boer, Fransien, additional, Kersting, Sabina, additional, Raa, Doreen te, additional, Issa, Djamila E., additional, Otten, Henny G., additional, Visser, Hein P.J., additional, Kater, Arnon P., additional, Goorhuis, Abraham, additional, and de Heer, Koen, additional

Published
2022
Full Text
View/download PDF

12. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe):primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

Author

Kersting, Sabina, Dubois, Julie, Nasserinejad, Kazem, Dobber, Johan A., Mellink, Clemens, van der Kevie-Kersemaekers, Anne Marie F., Evers, Ludo M., de Boer, Fransien, Koene, Harry R., Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A., van der Spek, Ellen, van der Straaten, Hanneke M., Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F.M., Visser, Hein P.J., Houtenbos, Ilse, Idink, Cecile A.M., Issa, Djamila E., Dompeling, Ellen C., van Zaanen, Henk C.T., Veelken, Hendrik, Levenga, Henriette, Tick, Lidwine W., Terpstra, Wim E., Tonino, Sanne H., Boyer, Michelle, Mobasher, Mehrdad, Levin, Mark David, Kater, Arnon P., Kersting, Sabina, Dubois, Julie, Nasserinejad, Kazem, Dobber, Johan A., Mellink, Clemens, van der Kevie-Kersemaekers, Anne Marie F., Evers, Ludo M., de Boer, Fransien, Koene, Harry R., Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A., van der Spek, Ellen, van der Straaten, Hanneke M., Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F.M., Visser, Hein P.J., Houtenbos, Ilse, Idink, Cecile A.M., Issa, Djamila E., Dompeling, Ellen C., van Zaanen, Henk C.T., Veelken, Hendrik, Levenga, Henriette, Tick, Lidwine W., Terpstra, Wim E., Tonino, Sanne H., Boyer, Michelle, Mobasher, Mehrdad, Levin, Mark David, and Kater, Arnon P.

Abstract

Background: Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to determine the activity and safety of 12 cycles of venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated patients with chronic lymphocytic leukaemia who were unfit for fludarabine-based treatment, and whether this could be guided by minimal residual disease status. Methods: We conducted an open-label, randomised, parallel-group, phase 2 trial (HOVON 139/GiVe) at 25 hospitals in the Netherlands. Eligible patients were aged 18 years or older with previously untreated chronic lymphocytic leukaemia, had an ECOG performance status of 0–2, and were unfit for fludarabine-based treatment. All patients received two debulking cycles of intravenous obinutuzumab (100 mg on day 1, 900 mg on day 2, and 1000 mg on days 8, 15, and day 1 of cycle two), followed by fixed-duration venetoclax plus obinutuzumab for 12 cycles (six cycles of intravenous obinutuzumab 1000 mg on day 1 and 12 during 28-day cycles of oral venetoclax, starting with a 5-week ramp-up and then 400 mg once daily until completion of cycle 12). Patients were then randomly assigned (1:1) by minimal residual disease status in peripheral blood, to receive either 12 cycles of venetoclax consolidation irrespective of minimal residual disease or venetoclax consolidation only if minimal residual disease was detected at randomisation. The primary endpoint was undetectable minimal residual disease in bone marrow and no progressive disease 3 months after end of consolidation treatment (or corresponding timepoint) by intention-to-treat. Safety was assessed in all patients who received at least one dose of any study drug. This is the primary endpoint analysis of this trial, which is ongoing and is registered with EudraCT (2015-004985-27). Findings: Between Oct 28, 2016, and May 31, 2018, 70 patients were enrolled

Published
2022

13. Sectoranalyse Netwerkbedrijven:Managementsamenvatting

Author

van Vuuren, C.V., Ybema, Jan Fekke, and de Visser, Hein

Subjects
sustainable employability
Abstract

CAO-partijen in de sector van NetWerkbedrijven (NWb) willen door een analyse van reeds beschikbaar materiaal en data een duidelijker beeld krijgen waar en in welke mate het knelt op het gebied van duurzame inzetbaarheid. Met als doel informatie te vergaren voor een sectoraal activiteitenplan.

Published
2021

14. Sectoranalyse Netwerkbedrijven: Managementsamenvatting

Author

van Vuuren, C.V., Ybema, Jan Fekke, de Visser, Hein, Department of Organisation, and RS-Research Line Resilience (part of LIRS program)

Subjects
sustainable employability
Abstract

CAO-partijen in de sector van NetWerkbedrijven (NWb) willen door een analyse van reeds beschikbaar materiaal en data een duidelijker beeld krijgen waar en in welke mate het knelt op het gebied van duurzame inzetbaarheid. Met als doel informatie te vergaren voor een sectoraal activiteitenplan.

Published
2021

15. Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.

Author

Raa, Doreen G. Te, van der Straten, Lina, van Gelder, Michel, Kersting, Sabina, Levin, Mark-David, Mous, Rogier, van der Straaten, Hanneke M., Nijziel, Marten R., van der Spek, Ellen, Posthuma, Eduardus F. M, Visser, Hein P.J, van der Klift, Marjolein, de Heer, Koen, Bellido, Mar, Doorduijn, Jeanette K., Bruns, Anke H.W, Raijmakers, Reinier A. P, and Kater, Arnon P.

Subjects
CHRONIC lymphocytic leukemia, DIAGNOSIS
Abstract

Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the Dutch-Belgium Haemato-Oncology Cooperative Group for Adults in the Netherlands (HOVON) necessitated revising the Dutch CLL guidelines. The current guideline is based on the expert opinion of the HOVON CLL working group members and focusses on well-designed clinical trials taking into account efficacy with special emphasis on toxicity, treatment duration and treatment intensity. This article provides recommendations on diagnosis, treatment strategies in front-line and relapsed setting and provides supportive care measurements during novel-based therapies as well as for infectious CLL-related complications. The recommendations presented here are intended to provide guidance for the management of CLL patients in the Netherlands, and take into account the availability of treatment strategies at the time of this publication. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

16. First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Author

Fürstenau, Moritz, Ritgen, Matthias, Robrecht, Sandra, Von Tresckow, Julia, Zhang, Can, Schilhabel, Anke, Gregor, Michael, Thornton, Patrick, Staber, Philipp Bernhard, Tadmor, Tamar, Lindström, Vesa, Juliusson, Gunnar, Janssens, Ann, Levin, Mark-David, Da Cunha-Bang, Caspar, Schneider, Christof, Goldschmidt, Neta, Vandenberghe, Elisabeth, Rossi, Davide, Benz, Rudolf A., Heintel, Daniel, Poulsen, Christian Bjørn, Christiansen, Ilse, Frederiksen, Henrik, Enggaard, Lisbeth, Posthuma, Eduardus, Issa, Djamila, Visser, Hein, Bellido, Mar, Kutsch, Nadine, Dürig, Jan, Stehle, Alexander, Voehringer, Matthias C., Böttcher, Sebastian, Schulte, Clemens, Simon, Florian, Fink, Anna-Maria, Fischer, Kirsten, Holmes, Emily, Kreuzer, Karl-Anton, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Hallek, Michael, Kater, Arnon P., Niemann, Carsten Utoft, and Eichhorst, Barbara F.

Published
2023
Full Text
View/download PDF

17. Treatment-specific risk of second malignancies in five-year survivors of diffuse large B-cell lymphoma.

Author

Geurts, Yvonne M., primary, Neppelenbroek, Suzanne I.M., additional, So-Osman, Cynthia, additional, Vermaat, Joost S.P., additional, van Spronsen, Dick Johan, additional, Plattel, Wouter J., additional, de Weijer, Roel J., additional, Verschueren, Karijn M.S., additional, Zijlstra, Josée M., additional, Koene, Harry R., additional, Nijziel, Marten R., additional, Schimmel, Erik C., additional, Böhmer, Lara H., additional, Ong, Francisca, additional, Visser, Hein, additional, van Kampen, Daphne, additional, Kersten, Marie José, additional, Aleman, Berthe M.P., additional, Van Leeuwen, Flora, additional, and Schaapveld, Michael, additional

Published
2021
Full Text
View/download PDF

18. Evaluatie van het Vitaliteitspact Universiteiten:Kwantitatief en kwalitatief onderzocht

Author

van Vuuren, C.V., van 't Hoff, Linda, Konngs, Henk, de Visser, Hein, and wolswijk, astrid

Abstract

Sinds 1 januari 2019 is een Vitaliteitspactregeling in gebruik op de universiteiten. Het Vitaliteitspact beoogt oudere medewerkers te ondersteunen om gezond en vitaal tot de AOW-leeftijd te blijven werken. De regeling biedt medewerkers de mogelijkheid (bij een volledige arbeidsduur) om vanaf 5 jaar voor de AOW gerechtigde leeftijd 0,2 fte (A-Variant) of 0,4 fte (Bvariant) minder te gaan werken tegen een salaris van 85% respectievelijk 70% van het oorspronkelijke salaris met behoudvan de volledige pensioenopbouw. In dit rapport doen wij verslag van een evaluatie van het Vitaliteitspact bij de universiteiten en kennisinstellingen. De evaluatie bestond uit een kwantitatief en kwalitatief deel.

Published
2020

19. Evaluatie van het Vitaliteitspact Universiteiten: Kwantitatief en kwalitatief onderzocht

Author

van Vuuren, C.V., van 't Hoff, Linda, Konngs, Henk, de Visser, Hein, wolswijk, astrid, Department of Organisation, and RS-Research Line Learning (part of LIRS program)

Abstract

Sinds 1 januari 2019 is een Vitaliteitspactregeling in gebruik op de universiteiten. Het Vitaliteitspact beoogt oudere medewerkers te ondersteunen om gezond en vitaal tot de AOW-leeftijd te blijven werken. De regeling biedt medewerkers de mogelijkheid (bij een volledige arbeidsduur) om vanaf 5 jaar voor de AOW gerechtigde leeftijd 0,2 fte (A-Variant) of 0,4 fte (Bvariant) minder te gaan werken tegen een salaris van 85% respectievelijk 70% van het oorspronkelijke salaris met behoud van de volledige pensioenopbouw. In dit rapport doen wij verslag van een evaluatie van het Vitaliteitspact bij de universiteiten en kennisinstellingen. De evaluatie bestond uit een kwantitatief en kwalitatief deel.

Published
2020

20. HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma

Author

Stevens, Wendy B.C., primary, Bakunina, Katerina, additional, Cuijpers, Marloes, additional, Chamuleau, Martine, additional, Beeker, Aart, additional, Fijnheer, Rob, additional, Hebart, Holger, additional, Visser, Hein P.J., additional, Doorduijn, Jeanette K., additional, Linton, Kim, additional, Dreyling, Martin, additional, de Jong, Daphne, additional, and Kersten, Marie José, additional

Published
2020
Full Text
View/download PDF

23. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

Author

Kater, Arnon P., primary, Kersting, Sabina, additional, van Norden, Yvette, additional, Dubois, Julie, additional, Dobber, Johan A., additional, Mellink, Clemens H., additional, Evers, Ludo M., additional, Croon-de Boer, Fransien, additional, Schreurs, John, additional, van der Spek, Ellen, additional, Visser, Hein, additional, Idink, Cecile, additional, Wittebol, Shulamiet, additional, Hoogendoorn, Mels, additional, Tonino, Sanne H., additional, Mobasher, Mehrdad, additional, and Levin, Mark-David, additional

Published
2018
Full Text
View/download PDF

24. The BETER survivorship care initiative for Hodgkin lymphoma; Tailored survivorship care for late effects of treatment

Author

Dekker, Nicky, Van'T Veer, Mars B., Aleman, Berthe M.P., Van Leeuwen, Flora E., Raemaekers, John M.M., Schaapveld, Michael, Opstal-Van Winden, Annemieke, De Boer, Jan Paul, Sombroek, Cherita, Poortmans, Philip, Van Der Maazen, Richard, Lugtenburg, P. J.Elly, Janus, Cecile, Noordijk, Ed, Krol, A. D.G.Stijn, Daniels, Laurien, Zijlstra, Josée, Meijer, Otto, Petersen, Eefke, Buter, Denise, De Weijer, Roel, Roesink, Judith, Kluin-Nelemans, J. C.Hanneke, Van Imhoff, Gustaaf, De Vries, Floriske, Beijert, Max, Kersten, Marie José, Oldenburger, Foppe, Dieleman, Edith, Schouten, Harry, Borger, Jacques, Van De Voorde, Lien, Verschueren, Karijn, Schippers, Maaike, Verbeeten, Bernard, Ong, Francisca, Dorresteijn, Lucille, Schimmel, Erik, Bouma, Paul, Muller, Karin, Lybeert, Marnix, Dompeling, Ellen, Manenschijn, Annelies, Vos-Westerman, J. Hanneke, Van Kampen, Daphne, Dielwart, Michel, Posthuma, Ward, Böhmer, Lara, Te Boome, Liane, Visser, Hein, Epidemiology and Data Science, EMGO - Quality of care, Hematology, CCA - Imaging and biomarkers, CCA - Disease profiling, CCA - Imaging, Radiation Oncology, VU University medical center, and Oral and Maxillofacial Surgery / Oral Pathology

Subjects
humanities
Abstract

The Dutch BETER consortium has established a national care infrastructure for Hodgkin lymphoma survivors. 'BETER' [the Dutch word for 'better'] stands for Better care after Hodgkin lymphoma (HL): Evaluation of longterm Treatment Effects and screening Recommendations. The survivorship care focuses on longterm effects of HL treatment. Over 10,000 HL survivors who were treated in the period spanning 19652008 have been identified. As part of the survivorship care initiative, specific BETER outpatient clinics have been set up. A dedicated website, www.beternahodgkin.nl, provides HL survivors with relevant information. The stakeholders of the BETER survivorship care programme aim to achieve an improved healthy life expectancy for patients treated for HL.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results